PathAI Introduces TumorDetect, an AI Solution to Automate Tumor Assessment and Case Prioritization For Anatomic Pathology Laboratories
TumorDetect detects regions of artifact (yellow overlays) invasive gastric adenocarcinoma (purple overlays) as well as tumor-associated stroma (orange overlays)
Driving Quality and Efficiency in Digital Pathology Workflows with AI-Enabled Tumor Assessment
Boston, MA – December 14, 2023 – PathAI, a global leader in AI-powered pathology, today announced TumorDetect on AISightTM, PathAI’s digital pathology image management system. TumorDetect is an AI-powered feature of AISight which automates the assessment and quantification of tumor across diverse tissue types. This product transforms pathology workflows by enabling case prioritization based on tumor content, helping pathologists to expedite case review, accelerate ordering of additional tests, and improving overall case turnaround time.
As cancer incidence and corresponding cancer biopsy volumes continue to rise year-over-year, TumorDetect is designed to ensure that pathologists’ focus is guided to cases with highest likelihood of cancer with the goal of more rapid confirmation of tumor presence (for example, through downstream IHC assessment). In addition to identifying cases and slides likely to contain tumor, the product generates overlay visualizations and slide-level quantifications to facilitate pathologist review. PathAI will be expanding this pilot across its network of 50+ laboratory and early access partners across diverse tumor types globally.
“Pathologists are facing increasing demands for faster case turnaround time, against a backdrop of increasing workload. TumorDetect is a game-changer in the field of pathology, empowering pathologists to efficiently prioritize cases based on tumor content”, said Andy Beck, MD, PhD, Cofounder & CEO, PathAI. “Our AI-powered solution is designed to expedite the case review process but also facilitates faster turnaround times for labs .”
“AI-enabled assist tools such as TumorDetect can help pathologists perform important daily tasks – tumor detection and cellularity assessment, which are crucial for biomarker testing and precision medicine”, said Marilyn Bui, MD, PhD, Senior Member in the Departments of Pathology and Machine Learning at Moffitt Cancer Center and Research Institute. “I am excited about the potential for AI-assisted tumor assessment to augment pathologists’ effectiveness in delivering quality results and streamlining pathology workflows.”
TumorDetect’s assessment and prioritization criteria are customizable, allowing pathologists to set personalized tumor content thresholds in line with their unique preferences and requirements. In addition to tumor cell quantification, TumorDetect also generates overlay visualizations highlighting hotspots of possible tumor on whole slide images (WSI). TumorDetect was developed on a dataset comprised of over 100,000 WSIs with over 6 million hand-drawn annotations from expert board-certified subspecialist pathologists, capturing the diversity of ways in which cancers appear in pathology WSIs. This feature, delivered through AISight, significantly aids pathologists during hotspot reviews, allowing for a more focused and targeted analysis of potentially cancerous regions.
This announcement follows the launch of several AI algorithm products including AIM-PD-L1TM and AIM-HER2TM for reproducible biomarker and disease severity assessment, ArtifactDetectTM for automated quality control, and AIM-TumorCellularityTM (AIM-TC) for whole-slide level assessment of tumor celllularity. PathAI’s comprehensive suite of eight AI product offerings is designed to power pathologist decision making while optimizing laboratory efficiency.
To learn more about AISight, PathAI’s image management system, or TumorDetect and its capabilities, please contact digitaldx@pathai.com
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com.
About AISight
AISight, introduced earlier this year by PathAI, is a comprehensive digital pathology image management system, currently offered for Research Use Only. AISight provides best-in-class image and case management, ingestion, and viewing while seamlessly enabling access and deployment of AI applications. AISight can also be integrated bidirectionally with laboratory information systems for streamlined workflow adoption. Anatomic pathology laboratories of all sizes and specialties – including health systems, reference laboratories, independent pathology labs, and academic medical centers – may utilize AISight.
TumorDetect, AISight, AIM-PD-L1, AIM-HER2, and AIM-TumorCellularity are For Research Use Only. Not for use in diagnostic procedures.
SOURCE: PathAI
